Decentralized Trials: Reshaping the Rare Disease Landscape
Clinical drug development is moving away from traditional approaches that rely on rare disease patients to travel long distances to clinical sites and toward a more patient-focused paradigm, one that highlights virtual and decentralized clinical trials (DCT). By bringing trials directly to patients instead of requiring patients to travel to sites, we can alleviate a primary burden of clinical trial participation and democratize clinical trial access. In this white paper, you’ll learn the following key points:
Xconomy
2 International Place #2610
Boston, MA 02110-4104
DOWNLOAD NOW: